In this episode of AVAC’s Px Pulse podcast series, Slim Abdool Karim, co-principal investigator of the landmark CAPRISA 004 study, talks about why designing trials with oral PrEP is a must—scientifically and ethically.
PrEP and Trial Design — A no brainer for some
Golden Age or Fools Gold?
In this episode of AVAC’s Px Pulse podcast series, Carl Dieffenbach, Director of NIH’s Division of AIDS, tells AVAC where he sees the most promise in the field of HIV prevention and what it will take to “put out the fire.”
AVAC Fellow Peter Mogere: HIV self-testing
2017 AVAC Advocacy Fellow Peter Mogere speaks on Kenya’s KUTV about HIV self-testing.
Watch the clip (17:29).
Px Wire July-September 2017, Vol. 10, No. 3
This issue of AVAC’s quarterly newsletter, Px Wire, is now available. Check it out for a deep dive into the data that suggest men who have sex with men may be able protected by oral PrEP, even if they don’t dose every day—and for the reasons why these data do not apply to women. You’ll also find out why messages about global AIDS are on our mind—and what we’d change about the current global conversation.
Investment in HIV Prevention Research & Development
Because money matters as much as messages, this Px Wire centerspread summarizes current investments, and trends over time, in HIV-prevention research and development. This full-color feature is excerpted from the recently-released report on HIV prevention research and development investment produced by AVAC and partners in the field.
South African HIV Prevention Research and Demonstration Sites
South Africa’s Trial Sites: An overview of HIV prevention research and demonstration sites in 2017, by location and intervention.
Evolving Context for HIV Prevention Research (Map)
A global map showing selected HIV prevention research and oral PrEP status.
Fighting HIV Drug Resistance in Uganda
AVAC Fellow Moses Supercharger has this primer on the upward trend of HIV drug resistance in Uganda, with action items for advocates.
Global HIV Prevention R&D Investment by Technology Category, 2000-2016
In 2016, funding for HIV prevention R&D decreased by 3 percent (US$35 million) from the previous year, falling to US$1.17 billion. Funding in 2016 signals the lowest annual investment in HIV prevention R&D in more than a decade.
Composition of the Global HIV Prevention R&D Investment Base, 2015-2016
The call for a more diverse base of funders in the prevention R&D landscape is not a new one, but recent trends display greater polarization and a more extreme funding imbalance. In 2016, 75 percent of the overall funding came from the US public sector. Together, the US public sector and the BMGF represented 88 percent of the total global investment in 2016, compared to 81 percent in 2015.
Excerpted from our HIV prevention research tracking report, visit here for all graphics from the report.